FDA approves Genentech's PD-L1 for bladder cancer

FDA granted accelerated approval to Tecentriq atezolizumab ( MPDL3280A) from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to treat locally

Read the full 210 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE